The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Renosen Pharmaceuticals Pvt Ltd, part of the promoter group of Senores Pharmaceuticals, bought 4,000 equity shares (0.009%) of the company through the open market on May 26, 2025. Before the acquisition, Renosen held 26,98,219 shares (5.86%); after the purchase, its holding rose to 27,02,219 shares (5.87%). This is a routine disclosure under SEBI's Takeover Regulations, reporting a very small increase in promoter group stake. The total share capital of Senores Pharmaceuticals remains unchanged at 4,60,53,588 equity shares of Rs. 10 each.
The acquisition is too small (0.009%) to materially affect the stock price or change the company's ownership structure. It signals mild promoter group confidence but is not significant in scale.